<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117988</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00101</org_study_id>
    <secondary_id>NCI-2009-00101</secondary_id>
    <secondary_id>CDR0000433593</secondary_id>
    <secondary_id>2004-0792</secondary_id>
    <secondary_id>6936</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R21CA117070</secondary_id>
    <nct_id>NCT00117988</nct_id>
  </id_info>
  <brief_title>17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well 17-AAG works in treating patients with relapsed or
      refractory anaplastic large cell lymphoma, mantle cell lymphoma, or Hodgkin's lymphoma. Drugs
      used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. Determine the complete and partial response rates and time to treatment failure in
      patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or
      classical Hodgkin's lymphoma treated with 17-N-allylamino-17-demethoxygeldanamycin (17-AAG).

      SECONDARY OBJECTIVES:

      I. Determine the safety of this drug in these patients. II. Determine the biologic effect of
      this drug on selected molecular targets in primary lymphoma cells from these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to disease type
      (anaplastic large cell lymphoma vs mantle cell lymphoma vs Hodgkin's lymphoma).

      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1,
      4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease
      progression or unacceptable toxicity. Patients experiencing disease regression after
      completion of 8 courses may receive 2 additional courses of treatment beyond their maximal
      response.

      After completion of study treatment, patients are followed every 3 months until disease
      progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Response</measure>
    <time_frame>Baseline to time to best response; Every 6 weeks</time_frame>
    <description>Number of participants who experience complete response or partial response. Partial Response=&gt;50% decrease in lympho node masses. Complete Response=&gt;-75% decrease in lymph node masses.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to and during study treatment

          -  Must have normal organ and marrow function

          -  Not a candidate for stem cell transplantation

          -  ECOG 0-2 OR Karnofsky 60-100%

          -  Bilirubin normal

          -  Creatinine normal

          -  Histologically or cytologically confirmed relapsed or refractory mantle cell lymphoma,
             anaplastic large cell lymphoma (CD30-positive disease), or classical Hodgkin's
             lymphoma

          -  Recovered from prior biologic therapy or autologous stem cell transplantation

          -  Prior antibody therapy within the past 3 months allowed

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
             recovered

          -  More than 4 weeks since prior radiotherapy (12 weeks for radioimmunotherapy) and
             recovered

          -  Recovered from prior investigational drugs

          -  Recovered from prior surgery

          -  More than 4 weeks since other prior anticancer therapy

          -  Concurrent low-molecular weight heparin is allowed

          -  Measurable disease, defined as &gt;= 1 unidimensionally measurable lesion &gt;= 20 mm

          -  Absolute neutrophil count &gt;= 1,500/mm3

          -  Received &gt;= 1, but =&lt; 3, prior treatment regimens for lymphoma (salvage therapy
             followed immediately by stem cell transplantation is considered 1 regimen).
             Single-agent monoclonal antibody therapy, cytokine therapy, or involved field
             radiotherapy are not considered prior treatment regimens. All prior treatments and
             prior antibody therapy within the past 3 months are recorded.

          -  Platelet count &gt;= 75,000/mm3

          -  AST and ALT =&lt; 1.5 times upper limit of normal

          -  Understand and provide signed informed consent.

        Exclusion Criteria:

          -  No cardiac arrhythmia or uncontrolled dysrhythmia

          -  No history of myocardial infarction within the past year

          -  No New York Heart Association class III or IV heart failure

          -  No other significant cardiac disease

          -  No paroxysmal nocturnal dyspnea

          -  No oxygen requirement

          -  No AIDS

          -  No history cardiac toxicity after receiving anthracyclines (e.g., doxorubicin
             hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine)

          -  No pulmonary lymphoma

          -  No known CNS lymphoma

          -  QTc &gt;/= 450 msec for men

          -  QTc &gt;/= 470 msec for women

          -  LVEF &lt;/= 40% by MUGA

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No symptomatic pulmonary disease requiring medication

          -  No significant pulmonary disease including chronic obstructive or restrictive
             pulmonary disease

          -  No dyspnea on or off exertion

          -  No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin
             hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine)

          -  Not pregnant or nursing

          -  No other uncontrolled illness

          -  No other active* malignancy except nonmelanoma skin cancer or carcinoma in situ of the
             cervix

          -  No prior allogeneic stem cell transplantation

          -  No history of allergic reaction to eggs

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No prior chest radiation or prior radiation that potentially included the heart in the
             field (e.g.,mantle).

          -  No concurrent medications that prolong or may prolong QTc

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapy

          -  No prior cardiac symptoms &gt;= grade 2

          -  No sufficiently compromised pulmonary status (i.e., DLCO =&lt; 80%)

          -  No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or
             ventricular fibrillation &gt;= 3 beats in a row)

          -  No prior pulmonary symptoms &gt;= grade 2

          -  HIV negative

          -  No active ischemic heart disease within 12 months.

          -  No congenital long QT syndrome.

          -  No left bundle branch block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>May 5, 2011</results_first_submitted>
  <results_first_submitted_qc>May 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2011</results_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 02/08/2005 through 05/08/2009. All participant recruitment attempted at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>17-AAG</title>
          <description>17-N-allylamino-17-demethoxygeldanamycin (17-AAG) 220 mg/m^2 intravenous (IV) over 1 hour on days 1, 4, 8, and 11, repeated every 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>17-AAG</title>
          <description>17-N-allylamino-17-demethoxygeldanamycin (17-AAG) 220 mg/m^2 intravenous (IV) over 1 hour on days 1, 4, 8, and 11, repeated every 21 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" lower_limit="25" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Response</title>
        <description>Number of participants who experience complete response or partial response. Partial Response=&gt;50% decrease in lympho node masses. Complete Response=&gt;-75% decrease in lymph node masses.</description>
        <time_frame>Baseline to time to best response; Every 6 weeks</time_frame>
        <population>Analysis was intention to treat (ITT). All participants with baseline and at least one post baseline target lesion measurement were included.</population>
        <group_list>
          <group group_id="O1">
            <title>17-AAG</title>
            <description>17-N-allylamino-17-demethoxygeldanamycin (17-AAG) 220 mg/m^2 intravenous (IV) over 1 hour on days 1, 4, 8, and 11, repeated every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Response</title>
          <description>Number of participants who experience complete response or partial response. Partial Response=&gt;50% decrease in lympho node masses. Complete Response=&gt;-75% decrease in lymph node masses.</description>
          <population>Analysis was intention to treat (ITT). All participants with baseline and at least one post baseline target lesion measurement were included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>17-AAG</title>
          <description>17-N-allylamino-17-demethoxygeldanamycin (17-AAG) 220 mg/m^2 intravenous (IV) over 1 hour on days 1, 4, 8, and 11, repeated every 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anas Younes, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>etubbs@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

